Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

ClinicalTrials.gov ID: NCT07690371

Public ClinicalTrials.gov record NCT07690371. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo. The estimated participant overall duration is approximately 15 months.

Study identification

NCT ID
NCT07690371
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Nektar Therapeutics
Industry
Enrollment
510 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 29, 2026 (Actual)
Primary completion
May 2028 (Estimated)
Completion
Dec 2028 (Estimated)
Last update posted
Sep 14, 2026

2026 – 2028

United States locations

U.S. sites
19
U.S. states
14
U.S. cities
18
Facility City State ZIP Site status
Nektar Investigative Site Phoenix Arizona 85037 Recruiting
Nektar Investigative Site North Little Rock Arkansas 72117-2916 Recruiting
Nektar Investigative Site Fountain Valley California 92708-3701 Recruiting
Nektar Investigative Site Los Angeles California 90025-7014 Recruiting
Nektar Investigative Site Boca Raton Florida 33486 Recruiting
Nektar Investigative Site St. Petersburg Florida 33714 Recruiting
Nektar Investigative Site Tampa Florida 33615-4537 Recruiting
Nektar Investigative Site Macon Georgia 31217-3865 Recruiting
Nektar Investigative Site Boise Idaho 83706-1337 Recruiting
Nektar Investigative Site Normal Illinois 61761-6280 Recruiting
Nektar Investigative Site Bowling Green Kentucky 42104 Recruiting
Nektar Investigative Site Owensboro Kentucky 42301 Recruiting
Nektar Investigative Site Lafayette Louisiana 70508 Recruiting
Nektar Investigative Site Omaha Nebraska 68144-5604 Recruiting
Nektar Investigative Site Clifton New Jersey 07013 Recruiting
Nektar Investigative Site New York New York 10023 Recruiting
Nektar Investigative Site New York New York 10128-0724 Recruiting
Nektar Investigative Site Wilmington North Carolina 28405-2375 Recruiting
Nektar Investigative Site Oklahoma City Oklahoma 73118-2872 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07690371, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 14, 2026 · Synced Oct 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07690371 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →